Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Microbot Medical ( (MBOT) ).
On July 8, 2025, Microbot Medical announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting in Strasbourg, France, from July 16-20. This event highlights the growing importance of robotics in endovascular procedures, with Microbot Medical using the platform to showcase its LIBERTY Endovascular Robotic System. The company is also preparing for the U.S. launch of LIBERTY, pending FDA 510(k) clearance, and is enhancing its sales and marketing efforts in anticipation of this decision.
The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to improve the quality of care for patients and providers globally.
Average Trading Volume: 2,690,878
Technical Sentiment Signal: Buy
Current Market Cap: $91.31M
For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.